AstraZeneca’s Enhertu has emerged as the top-selling new drug in India, generating ₹58 crore in sales during its first year in 2024.
The remarkable success highlights the rising incidence of cancer in the country, contributing to the growing demand for oncology treatments.
Pharmaceutical Market Growth in India
The Indian pharmaceutical market saw a significant boost, with over 3,100 new drug brands launched, contributing to a total of ₹1,097 crore in sales.
The market as a whole surpassed ₹2.2 lakh crore, experiencing a steady growth rate of 8%.
Gastrointestinal Segment Leads Growth
The gastrointestinal segment experienced the highest growth, raking in ₹167 crore in sales. This was closely followed by oncology therapies, which generated ₹150 crore, underscoring the increasing focus on cancer treatment in India.
Top-Selling Brands and Trends
While Enhertu claimed the top spot for new drug sales, GSK’s Augmentin continued to be the best-selling brand across the broader pharmaceutical market. The overall expansion of the sector reflects increasing healthcare demands, particularly in oncology and cardiac care.
Steady Expansion of the Pharmaceutical Sector
As reported by newsminimalist.com, the Indian pharmaceutical sector is steadily expanding, fuelled by the launch of new products and rising healthcare needs. The growth is particularly noticeable in oncology and cardiac care, areas poised for further development in the coming years.
